Research published in the British Medical Journal analyzed health records from 606,434 U.S. veterans with type 2 diabetes who were prescribed either GLP-1 receptor agonists or SGLT2 inhibitors and monitored for up to three years.
Study Shows GLP-1 Drugs Could Be Linked to Lower Addiction Risk